What Analysts Are Saying About Zymeworks Stock
Portfolio Pulse from Benzinga Insights
Analysts have mixed ratings for Zymeworks (NASDAQ:ZYME), with a recent average price target of $13.75, up from $13.00. The stock has one bullish rating and three indifferent ratings. Analysts have adjusted their price targets, with the highest at $21.00 and the lowest at $10.00. Zymeworks is a clinical-stage biopharmaceutical company with significant revenue growth but challenges in asset utilization.
October 22, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zymeworks has received mixed analyst ratings, with a recent average price target increase to $13.75. The stock has one bullish and three indifferent ratings, indicating varied sentiment. Analysts have adjusted price targets, with the highest at $21.00 and the lowest at $10.00.
The mixed analyst ratings and the increase in the average price target suggest a neutral short-term impact on Zymeworks' stock price. The presence of a bullish rating and a higher price target could provide some upward pressure, but the indifferent ratings balance this out.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100